ITOC 2020 | Potential of ADAR pathway in immunotherapy

Jeffrey Ishizuka, MD, DPhil, Yale School of Medicine, New Haven, CT, highlights the potential of the ADAR1 pathway in immunotherapy. Dr Ishizuka mentions different mechanisms of resistance to immunotherapy and explains how using functional genomics (such as CRISPR/Cas9) has enabled for the identification of ADAR1. Many patients do not respond to immunotherapy due to MHC-I down-regulation, but deleting ADAR1 restores response to immunotherapy. Dr Ishizuka provides an in-depth explanation of the mechanism of action of the ADAR1 pathway and its potential role in immunotherapy. This interview took place during the 7th Immunotherapy of Cancer Conference (ITOC) 2020.